Basic information Safety Supplier Related

Lenalidomide-d5

Basic information Safety Supplier Related

Lenalidomide-d5 Basic information

Product Name:
Lenalidomide-d5
Synonyms:
  • 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-d5
  • 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione-d5
  • CC-5013-d5
  • D5-Lenalidomide
CAS:
1227162-34-6
MF:
C13H8D5N3O3
MW:
264.29142889
Mol File:
1227162-34-6.mol
More
Less

Lenalidomide-d5 Chemical Properties

storage temp. 
Store at -20°C
solubility 
DMSO: soluble,Methanol: soluble
form 
A solid
color 
White to off-white
More
Less

Lenalidomide-d5 Usage And Synthesis

Uses

Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

Biological Activity

Lenalidomide-d5 is intended for use as an internal standard for the quantification of lenalidomide by GC- or LC-MS. Lenalidomide is related to thalidomide and, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.1 It also induces proliferation and enhances the functional capacity of T lymphocytes, amplifying co-stimulatory signaling pathways.2 Lenalidomide is effective in hematologic cancers, including lymphomas and myelomas.3,4

IC 50

Cereblon

References

1.Kim, K., An, S., Cha, H.J., et al.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cellsOncol.Lett.5(2)588-596(2013) 2.McDaniel, J.M., Pinilla-Ibarz, J., and Epling-Burnette, P.K.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesAdv. Hematol.513702(2012) 3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012) 4.Merli, M., Ferrario, A., Basilico, C., et al.Novel agents in indolent lymphomasTher.Adv.Hematol.4(2)133-148(2013)

Lenalidomide-d5Supplier

Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Hubei Yangxin Medical Technology Co., Ltd.
Tel
15374522761
Email
3003392093@yongstandards.com
Shenzhen SUNGENING Bio-Medical Co., Ltd.
Tel
0755-0755-28967200-8062 13631290199
Email
wxf@sungening.com
Nanjing Shizhou Biology Technology Co.,Ltd
Tel
025-025-85560043 17301488900
Email
info@synzest.com
Shanghai YuZn Pharm. Technology Co.,Ltd.
Tel
15921286451; 15921286451
Email
2010681527@qq.com